[CLSTR]
< Back to situations

[ORGANIZATION]

Gilead Sciences

Featured in 20 tracked stories · first seen

Situations

[ACTIVE] [HEALTH] [KR] [US]

GC Cell advances GCC2005 CAR-NK therapy development

3 clusters · 6 sources · last updated

Latest: GC Cell presents GCC2005 clinical trial results at ICBMT 2026

GC Cell is advancing its GCC2005 CAR-NK cell therapy, a CD5-targeted allogeneic treatment for refractory T-cell lymphoma. The company has partnered with QuantHealth to use AI-based clinical trial simulations to optimize

[ACTIVE] [HEALTH] [ZA] [AR] [BO]

Lenacapavir HIV prevention rollout and efficacy

7 clusters · 29 sources · last updated

Latest: HIV testing expands in Paraguay as Oruro reports rising cases

Lenacapavir, a long-acting injectable medication for HIV pre-exposure prophylaxis (PrEP), has demonstrated high efficacy in clinical trials. The drug, which requires only two doses per year, is administered via abdominal

[QUIET] [HEALTH] [US] [IN]

Gilead Sciences HIV treatment developments

2 clusters · 4 sources · last updated

Latest: Gilead Sciences receives FDA approval for new once-daily HIV pill

The U.S. Food and Drug Administration (FDA) has approved Gilead Sciences’ Bixlenvo, a once-daily single-pill HIV treatment. The medication combines bictegravir and lenacapavir to assist adult patients who have suppressed

[QUIET] [HEALTH] [GR]

Oncology drug withdrawals in Greece

4 clusters · 14 sources · last updated

Latest: Greece healthcare faces drug shortages and hospital delays

Pharmaceutical company Gilead has announced plans to withdraw its innovative breast cancer drug, Trodelvy (sacituzumab govitecan), from the Greek market by the end of the year. The medication is used to treat metastatic,

Also covered in